Literature DB >> 21905078

Stem cell technology for neurodegenerative diseases.

J Simon Lunn1, Stacey A Sakowski, Junguk Hur, Eva L Feldman.   

Abstract

Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Year:  2011        PMID: 21905078      PMCID: PMC3177143          DOI: 10.1002/ana.22487

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  80 in total

1.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

2.  Single factors direct the differentiation of stem cells from the fetal and adult central nervous system.

Authors:  K K Johe; T G Hazel; T Muller; M M Dugich-Djordjevic; R D McKay
Journal:  Genes Dev       Date:  1996-12-15       Impact factor: 11.361

3.  Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice.

Authors:  Jun Yan; Leyan Xu; Annie M Welsh; David Chen; Thomas Hazel; Karl Johe; Vassilis E Koliatsos
Journal:  Stem Cells       Date:  2006-04-27       Impact factor: 6.277

Review 4.  Dementia epidemiology.

Authors:  Walter A Kukull; James D Bowen
Journal:  Med Clin North Am       Date:  2002-05       Impact factor: 5.456

5.  Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation.

Authors:  Svitlana Garbuzova-Davis; Alison E Willing; Tanja Zigova; Samuel Saporta; Eleanor B Justen; Jennifer C Lane; Jennifer E Hudson; Ning Chen; Cyndy D Davis; Paul R Sanberg
Journal:  J Hematother Stem Cell Res       Date:  2003-06

Review 6.  Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.

Authors:  P Nigel Leigh; Michael Swash; Yasuo Iwasaki; Albert Ludolph; Vincent Meininger; Robert G Miller; Hiroshi Mitsumoto; Pamela Shaw; Kunio Tashiro; Leonard Van Den Berg
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2004-06

7.  Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry.

Authors:  Leyan Xu; David K Ryugo; Tan Pongstaporn; Karl Johe; Vassilis E Koliatsos
Journal:  J Comp Neurol       Date:  2009-06-01       Impact factor: 3.215

8.  Embryonic stem cell-specific microRNAs promote induced pluripotency.

Authors:  Robert L Judson; Joshua E Babiarz; Monica Venere; Robert Blelloch
Journal:  Nat Biotechnol       Date:  2009-04-12       Impact factor: 54.908

9.  Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.

Authors:  E Garbayo; C N Montero-Menei; E Ansorena; J L Lanciego; M S Aymerich; M J Blanco-Prieto
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

10.  Somatic coding mutations in human induced pluripotent stem cells.

Authors:  Athurva Gore; Zhe Li; Ho-Lim Fung; Jessica E Young; Suneet Agarwal; Jessica Antosiewicz-Bourget; Isabel Canto; Alessandra Giorgetti; Mason A Israel; Evangelos Kiskinis; Je-Hyuk Lee; Yuin-Han Loh; Philip D Manos; Nuria Montserrat; Athanasia D Panopoulos; Sergio Ruiz; Melissa L Wilbert; Junying Yu; Ewen F Kirkness; Juan Carlos Izpisua Belmonte; Derrick J Rossi; James A Thomson; Kevin Eggan; George Q Daley; Lawrence S B Goldstein; Kun Zhang
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

View more
  79 in total

Review 1.  Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches.

Authors:  Daniel Garzón; Ricardo Cabezas; Nelson Vega; Marcos Ávila-Rodriguez; Janneth Gonzalez; Rosa Margarita Gómez; Valentina Echeverria; Gjumrakch Aliev; George E Barreto
Journal:  J Mol Neurosci       Date:  2016-01-23       Impact factor: 3.444

2.  Information theoretical analysis of aging as a risk factor for heart disease.

Authors:  David Blokh; Ilia Stambler
Journal:  Aging Dis       Date:  2015-06-01       Impact factor: 6.745

3.  The Critical Need to Promote Research of Aging and Aging-related Diseases to Improve Health and Longevity of the Elderly Population.

Authors:  Kunlin Jin; James W Simpkins; Xunming Ji; Miriam Leis; Ilia Stambler
Journal:  Aging Dis       Date:  2014-12-15       Impact factor: 6.745

Review 4.  Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy.

Authors:  Su M Metcalfe; Sean Bickerton; Tarek Fahmy
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

5.  Stem cells and stroke-how glowing neurons illuminate new paths.

Authors:  Dinko Mitrečić; Ivan Alić; Dunja Gorup
Journal:  Neurogenesis (Austin)       Date:  2017-05-16

Review 6.  Biological Products: Cellular Therapy and FDA Approved Products.

Authors:  Ali Golchin; Tahereh Zarnoosheh Farahany
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

Review 7.  Cell replacement therapy is the remedial solution for treating Parkinson's disease.

Authors:  Venkatesan Dhivya; Vellingiri Balachandar
Journal:  Stem Cell Investig       Date:  2017-06-30

Review 8.  Combining topographical and genetic cues to promote neuronal fate specification in stem cells.

Authors:  Erin K Purcell; Youssef Naim; Amy Yang; Michelle K Leach; J Matthew Velkey; R Keith Duncan; Joseph M Corey
Journal:  Biomacromolecules       Date:  2012-10-26       Impact factor: 6.988

9.  Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.

Authors:  Yanyan Peng; Benjamin Liou; Venette Inskeep; Rachel Blackwood; Christopher N Mayhew; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

Review 10.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.